Topic Hub
23 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 23 of 23 clinical reviews.
A physician-reviewed deep dive into how resmetirom (Rezdiffra) affects appetite and food cravings in MASH patients, with data from MAESTRO-NASH, mechanism of action detail, and practical clinical guidance.
Read clinical reviewA physician-level review of how resmetirom (Rezdiffra) affects autoimmune conditions, including thyroid autoimmunity, immune-mediated hepatitis, and drug interactions relevant to patients with MASH and co-existing autoimmune disease.
Read clinical reviewA physician-reviewed analysis of how resmetirom (Rezdiffra) affects bone mineral density and bone turnover markers in MASH patients, with primary-literature citations and clinical guidance.
Read clinical reviewA physician-level analysis of the cancer risk signals observed with resmetirom (Rezdiffra) in MAESTRO-NASH and post-approval data, including hepatocellular carcinoma, thyroid neoplasia, and regulatory context.
Read clinical reviewA physician-level review of resmetirom's long-term cardiovascular effects, including lipid changes, MASH-CVD mechanisms, MAESTRO-NASH trial data, and what to expect beyond 52 weeks of therapy.
Read clinical reviewA detailed clinical review of how resmetirom (Rezdiffra) affects cognitive function, including MAESTRO-NASH trial data, thyroid hormone receptor biology, and what patients and clinicians need to know.
Read clinical reviewA physician-reviewed comparison of branded Rezdiffra (resmetirom) versus compounded resmetirom for MASH, covering FDA approval, pharmacology, safety, and prescribing guidance.
Read clinical reviewA GRADE-level analysis of resmetirom's clinical evidence for MASH, covering MAESTRO-NASH trial data, histological endpoints, safety, and what the evidence quality means for prescribing decisions.
Read clinical reviewA clinical deep-dive into resmetirom (Rezdiffra) hair loss, alopecia, rash, and other dermatologic adverse effects reported in MAESTRO-NASH and post-marketing surveillance, with dosing context and management guidance.
Read clinical reviewA physician-reviewed deep dive into how resmetirom (Rezdiffra) affects liver function in MASH, covering MAESTRO-NASH trial data, ALT/AST changes, histological outcomes, fibrosis regression, and safety signals.
Read clinical reviewA physician-reviewed deep dive into how resmetirom (Rezdiffra) affects mood, cognition, sleep, and psychiatric risk in MASH patients, with primary-literature citations and clinical guidance.
Read clinical reviewA physician-level review of how resmetirom (Rezdiffra) alters hepatic metabolism, mitochondrial thermogenesis, and lipid oxidation in MASH patients, with primary-literature citations throughout.
Read clinical reviewA physician-reviewed deep dive into resmetirom (Rezdiffra) dosing, the MAESTRO-NASH trial data, FDA-approved dose levels, and whether any clinical evidence supports microdosing in MASH.
Read clinical reviewA clinician-level guide to muscle preservation during resmetirom (Rezdiffra) therapy for MASH: mechanism, trial data, monitoring protocols, and practical strategies to protect lean mass.
Read clinical reviewMD-level guide to diagnosing and managing resmetirom plateau and non-response in MASH patients: dose optimization, adherence checks, combination strategies, and when to escalate care.
Read clinical reviewA comprehensive clinical review of resmetirom (Rezdiffra) use after bariatric surgery, covering pharmacokinetics, drug interactions, dosing adjustments, and evidence from MAESTRO-NASH and related trials.
Read clinical reviewA physician-level guide to the Rezdiffra (resmetirom) pre-surgery hold window, including pharmacokinetics, thyroid-axis considerations, bleeding risk, anesthetic interactions, and a practical perioperative protocol.
Read clinical reviewWhat happens when you stop resmetirom? This clinician-reviewed guide covers the evidence on MASH rebound, lipid changes, thyroid-axis effects, and how to taper or transition safely after discontinuing Rezdiffra.
Read clinical reviewA clinician-level review of resmetirom's renal effects in MASH patients: MAESTRO-NASH data, mechanistic rationale, safety signals, and monitoring guidance for prescribers.
Read clinical reviewA physician-reviewed deep dive into how resmetirom (Rezdiffra) affects sexual function in MASH patients, covering trial data, thyroid receptor biology, hormonal pathways, and practical clinical guidance.
Read clinical reviewA clinician-level review of how resmetirom (Rezdiffra) affects sleep architecture in MASH patients, drawing on MAESTRO-NASH trial data, thyroid-hormone receptor biology, and emerging polysomnography evidence.
Read clinical reviewMD/PharmD-level guidance on dosing resmetirom (Rezdiffra) across time zones, managing missed doses while traveling, drug interactions at altitude, and hepatic monitoring logistics for patients with MASH.
Read clinical reviewA week-by-week clinical guide to the first month on resmetirom (Rezdiffra), what labs change, which side effects peak and fade, and what MAESTRO-NASH data say about early response.
Read clinical review